[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
September 5, 2012

European Drug Agency Works to Improve Transparency, but Skepticism Remains

JAMA. 2012;308(9):850-851. doi:10.1001/2012.jama.10451

Following considerable pressure over policies related to the accessibility of unpublished clinical trial data in its database and conflicts of interest for its officials (Hampton T. JAMA. 2011;306[6]:593-595), the European Medicines Agency (EMA) is taking steps to increase transparency.

As a part of this effort, in July the EMA, the European counterpart to the US Food and Drug Administration (FDA), announced that it will release the agendas and minutes of its scientific committee meetings. “This latest initiative is an important part of opening up our operations, to reinforce the trust and reputation of the Agency as a public health body,” said Executive Director Guido Rasi, MD, in a press statement (http://tinyurl.com/bn4udam).